PA
TENX icon

Perceptive Advisors’s Tenax Therapeutics TENX Stock Holding History

Perceptive Advisors’s Portfolio TENX Stock Details TENX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.7M Buy
1,700,000
+252,218
+17% +$3.22M 0.37% 54
2026
Q1 		$23.2M Buy
1,447,782
+1,008,640
+230% +$13.6M 0.45% 48
2025
Q4 		$5.35M Buy
+439,142
New +$3.82M 0.1% 92

Other funds holding TENX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Perceptive Advisors's TENX Position: Q2 2026 in Review

Perceptive Advisors increased its Tenax Therapeutics (TENX) stake by 17% in Q2 2026, buying an estimated $3.22M and bringing the position to 1,700,000 shares worth $24.7M. The position accounts for 0.37% of the portfolio, ranked #54.

Perceptive Advisors first reported a position in TENX in Q4 2025 and has held it in 3 quarters since. 111 funds tracked by Wall St. Rank hold TENX as of Q2 2026.

  • Perceptive Advisors held 1,700,000 shares of Tenax Therapeutics worth $24.7M as of Q2 2026.
  • Perceptive Advisors bought 252,218 Tenax Therapeutics shares in Q2 2026, an estimated $3.22M.
  • Tenax Therapeutics made up 0.37% of Perceptive Advisors's portfolio in Q2 2026, its #54 holding.
  • Perceptive Advisors first reported a position in Tenax Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 111 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q2 2026.

Based on Perceptive Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.